- Home
- TLPH vs SNSE Comparison
TLPH vs SNSE Comparison
Compare TLPH & SNSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLPH
- SNSE
- Stock Information
- Founded
- TLPH 2005
- SNSE 2005
- Country
- TLPH United States
- SNSE United States
- Employees
- TLPH N/A
- SNSE N/A
- Industry
- TLPH Biotechnology: Pharmaceutical Preparations
- SNSE Biotechnology: Pharmaceutical Preparations
- Sector
- TLPH Health Care
- SNSE Health Care
- Exchange
- TLPH Nasdaq
- SNSE Nasdaq
- Market Cap
- TLPH 12.7M
- SNSE 12.3M
- IPO Year
- TLPH 2011
- SNSE 2021
- Fundamental
- Price
- TLPH $0.51
- SNSE $0.48
- Analyst Decision
- TLPH Strong Buy
- SNSE Strong Buy
- Analyst Count
- TLPH 2
- SNSE 3
- Target Price
- TLPH $4.50
- SNSE $4.33
- AVG Volume (30 Days)
- TLPH 108.9K
- SNSE 257.6K
- Earning Date
- TLPH 11-13-2024
- SNSE 11-14-2024
- Dividend Yield
- TLPH N/A
- SNSE N/A
- EPS Growth
- TLPH N/A
- SNSE N/A
- EPS
- TLPH N/A
- SNSE N/A
- Revenue
- TLPH $281,000.00
- SNSE N/A
- Revenue This Year
- TLPH N/A
- SNSE N/A
- Revenue Next Year
- TLPH N/A
- SNSE N/A
- P/E Ratio
- TLPH N/A
- SNSE N/A
- Revenue Growth
- TLPH N/A
- SNSE N/A
- 52 Week Low
- TLPH $0.50
- SNSE $0.38
- 52 Week High
- TLPH $1.61
- SNSE $1.94
- Technical
- Relative Strength Index (RSI)
- TLPH 29.73
- SNSE 50.54
- Support Level
- TLPH $0.64
- SNSE $0.42
- Resistance Level
- TLPH $0.69
- SNSE $0.50
- Average True Range (ATR)
- TLPH 0.06
- SNSE 0.04
- MACD
- TLPH -0.01
- SNSE 0.00
- Stochastic Oscillator
- TLPH 1.54
- SNSE 76.89
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
About SNSE Sensei Biotherapeutics Inc.
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing highly selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101, SNS-102, SNS-103, SNS-20.